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Abstract 
Background: Iron deficiency (ID) and malaria co-exist in tropical regions and both contribute to high rates of anae-
mia in young children. It is unclear whether iron fortification combined with intermittent preventive treatment (IPT) of 
malaria would be an efficacious strategy for reducing anaemia in young children.
Methods: A 9-month cluster-randomised, single-blinded, placebo-controlled intervention trial was carried out in 
children aged 12–36 months in south-central Côte d’Ivoire, an area of intense and perennial malaria transmission. 
The study groups were: group 1: normal diet and IPT-placebo (n = 125); group 2: consumption of porridge, an iron-
fortified complementary food (CF) with optimised composition providing 2 mg iron as NaFeEDTA and 3.8 mg iron as 
ferrous fumarate 6 days per week (CF-FeFum) and IPT-placebo (n = 126); group 3: IPT of malaria at 3-month intervals, 
using sulfadoxine-pyrimethamine and amodiaquine and no dietary intervention (n = 127); group 4: both CF-FeFum 
and IPT (n = 124); and group 5: consumption of porridge, an iron-fortified CF with the composition currently on the 
Ivorian market providing 2 mg iron as NaFeEDTA and 3.8 mg iron as ferric pyrophosphate 6 days per week (CF-FePP) 
and IPT-placebo (n = 127). The primary outcome was haemoglobin (Hb) concentration. Linear and logistic regression 
mixed-effect models were used for the comparison of the five study groups, and a 2 × 2 factorial analysis was used to 
assess treatment interactions of CF-FeFum and IPT (study groups 1–4).
Results: After 9 months, the Hb concentration increased in all groups to a similar extent with no statistically signifi-
cant difference between groups. In the 2 × 2 factorial analysis after 9 months, no treatment interaction was found on 
Hb (P = 0.89). The adjusted differences in Hb were 0.24 g/dl (95 % CI −0.10 to 0.59; P = 0.16) in children receiving IPT 
and −0.08 g/dl (95 % CI −0.42 to 0.26; P = 0.65) in children receiving CF-FeFum. At baseline, anaemia (Hb <11.0 g/dl) 
was 82.1 %. After 9 months, IPT decreased the odds of anaemia (odds ratio [OR], 0.46 [95 % CI 0.23–0.91]; P = 0.023), 
whereas iron-fortified CF did not (OR, 0.85 [95 % CI 0.43–1.68]; P = 0.68), although ID (plasma ferritin <30 μg/l) was 
decreased markedly in children receiving iron fortified CF (OR, 0.19 [95 % CI 0.09–0.40]; P < 0.001).
Conclusions: IPT alone only modestly decreased anaemia, but neither IPT nor iron fortified CF significantly improved 
Hb concentration after 9 months. Additionally, IPT did not augment the effect of the iron fortified CF. CF fortified with 
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Background
Anaemia in sub-Saharan Africa has many aetiologies, 
but iron deficiency (ID) and malaria are considered to 
be the major causes [1]. ID has been estimated to be 
responsible for more than one-third, and Plasmodium 
falciparum malaria for 24 % of all anaemia cases [1]. P. 
falciparum is highly endemic in rural Côte d’Ivoire [2] 
and is a major risk factor for anaemia in young children 
[3]. The proportion of anaemia attributed to these two 
causes varies with setting and population group [3, 4], 
and anaemia at the individual level may well result from 
both aetiologies.
Anaemia can be reduced in settings of seasonal trans-
mission by intermittent preventive treatment (IPT) of 
malaria [5]. Iron fortification may reduce the prevalence 
of anaemia in children aged below 2  years [6], but its 
effectiveness in sub-Saharan Africa remains uncertain. 
Iron stable isotope studies have reported that inflamma-
tion during afebrile malaria in women [7] and children 
[8] increases circulating hepcidin and decreases iron 
absorption. Therefore, IPT of malaria might improve the 
response to iron fortification in areas where malaria is 
highly endemic.
The aim of this study was to assess the effect of a com-
bination of two highly bioavailable iron compounds 
[9] (i.e. CF-FeFum: ferrous fumarate combined with 
NaFeEDTA) added to a cereal-based complemen-
tary food (CF) and IPT of malaria using sulfadoxine-
pyrimethamine and amodiaquine (SP/AQ) administered 
once every 3 months. The interventions were given alone 
or in combination. The primary and secondary outcomes 
were assessed for treatment interaction using a 2 × 2 fac-
torial analysis. The primary outcome measure was hae-
moglobin (Hb) concentration. Secondary outcomes were 
iron status markers and Plasmodium prevalence. The 
study was conducted in children aged 12–36 months liv-
ing in a rural part of south-central Côte d’Ivoire, where 
malaria transmission is perennial. The hypothesis was 
that a combined intervention with IPT of malaria and 
iron fortified CF would reduce anaemia and ID preva-
lence to a greater extent than either intervention alone. 
A fifth study group was included to test the efficacy of 
the combination of NaFeEDTA and ferric pyrophosphate 
(CF-FePP), a combination that is currently being used on 
the Ivorian market. Ferric pyrophosphate is considered to 
have a lower bioavailability than ferrous fumarate [9].
Methods
Study design and participants
This 9-month cluster-randomised, single-blinded, pla-
cebo-controlled intervention trial was conducted in 
the Taabo health and demographic surveillance system 
(HDSS) in south-central Côte d’Ivoire [10]. Recently it 
has been reported that the leading causes of death among 
children below 5  years of age in the Taabo HDSS are 
malaria, followed by acute respiratory tract infections and 
HIV/AIDS [11]. Malaria transmission is perennial with 
peaks occurring in the large rainy season (from April to 
August) and in the small rainy season (September/Octo-
ber). The prevalence of P.  falciparum infection ranges 
between 35 and 77 %, depending on season and age group 
[12, 13]. From the Taabo HDSS database, we identified 
840 children aged 12–36  months in five villages, which 
were invited for baseline screening (Fig. 1) from mid-April 
to mid-May 2012. Inclusion criteria were: (1) Hb ≥7 g/dl; 
(2) no major chronic illnesses; (3) anticipated residence in 
the area for the entire study duration; and (4) no known 
allergies to sulfadoxine, pyrimethamine and amodiaquine.
At baseline screening, 629 eligible children were iden-
tified and were grouped into 40 clusters based on prox-
imity of their residence, with at least five clusters in each 
of the five villages and from 13 to 18 children in each 
cluster. Then the clusters were randomly assigned to five 
study groups by drawing cluster numbers from an opaque 
hat (“urn randomisation”) together with village authori-
ties acting as witnesses. This public randomisation pro-
cess was implemented to avoid any feelings of unfairness 
among the village population. Allocation ratio was 1:1 
for all five study groups. The study groups were: group 
1: normal diet (no dietary intervention) +  IPT-placebo; 
group 2: iron fortified CF-FeFum +  IPT-placebo; group 
3: normal diet  +  IPT; group 4: CF-FeFum  +  IPT; and 
group 5: CF-FePP  +  IPT-placebo. Interventions lasted 
for 9 months.
Ethical considerations
The study was approved by the ethics committees of 
ETH Zurich (reference no. EK 2009-N-19) and Côte 
highly bioavailable iron improved iron status but not Hb concentration, despite three-monthly IPT of malaria. Thus, 
further research is necessary to develop effective combination strategies to prevent and treat anaemia in malaria 
endemic regions.
Trial registration: http://www.clinicaltrials.gov; identifier NCT01634945; registered on July 3, 2012.
Keywords: Anaemia, Complementary food, Côte d’Ivoire, Haemoglobin, Intermittent preventive treatment, Iron 
deficiency, Iron fortification, Malaria, Plasma ferritin, Plasmodium falciparum
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d’Ivoire (reference no. 061 MSLS/CNER). Village and 
health authorities, and parents/guardians of participat-
ing children were informed about the purpose, pro-
cedures, and potential risks and benefits of the study. 
Parental written informed consent was obtained for 
each child before randomisation. The trial was regis-
tered at clinicaltrials.gov (identifier NCT01634945). An 
independent data safety and monitoring board assessed 
study progress, provided expertise and assessed the 
safety of the interventions.
Complementary food production, preparation and feeding
The roller-dried maize- and soy-flour based CF was pro-
duced at Protein Kissèe-La (PKL) in Abidjan. Detailed 
porridge production procedures and composition are 
described in additional tables (see Additional file 1). The 
iron fortified CF contained 2.0  mg iron as NaFeEDTA, 
3.8 mg iron as ferrous fumarate, and 0.6 mg native iron 
in a daily serving of 25 g dry weight porridge. The com-
mercial iron fortified CF-FePP (study group 5) con-
tained 2.0  mg iron as NaFeEDTA, 3.8  mg iron as ferric 
pyrophosphate, and 0.6 mg native iron in a daily serving 
of 25  g dry weight porridge (see Additional file  1). The 
children consumed the porridge once a day in the early 
morning, 6  days a week providing 38.4  mg fortification 
iron per week (6.4  mg per serving). The native and for-
tificant iron dose of 6.4 mg per day covered 110 % of the 
recommended nutrient intake (RNI) for children aged 
1–3 years, assuming an intermediate iron bioavailability 
of 10 % [14]. Children assigned to study groups 2 and 4 
684 children were assessed for eligibility
629 assigned to 40 clusters, clusters randomly assigned to 5 study groups
Group 4: CF-FeFum + IPT
124 children in 8 clusters
Group 2: CF-FeFum
126 children in 8 clusters
Group 3: IPT 
127 children in 8 clusters
Group 1: control 
125 children in 8 clusters
114 completed 6-month 
follow-up
111 completed 6-month 
follow-up
103 completed 6-month 
follow-up
104 completed 6-month 
follow-up
82 children completed study 
and 124 were included in the 
analysis  
81 children completed study 
and 126 were included in the 
analysis  
77 children completed study 
and 127 were included in the 
analysis  
76 children completed study 
and 125 were included in the 
analysis 
Lost to first follow-up
- 5 moved away
- 3 refused 
- 1 died
Lost to first follow-up
- 6 moved away
- 6 refused 
- 2 died
Lost to first follow-up
- 11 moved away
- 10 refused 
- 1 died
Lost to first follow-up
- 15 moved away
- 5 refused 
Lost to second follow-up
- 16 moved away
- 14 refused 
- 1 died
Lost to second follow-up
- 8 moved away
- 19 refused 
- 1 died
Lost to second follow-up
- 15 moved away
- 10 refused 
Lost to second follow-up
- 13 moved away
- 14 refused 
55 excluded:
- 18 refused to participate
- 7 failed to take blood
- 1 severely dehydrated
- 29 children had Hb conc. <7 g/dl
840 children aged 12-36 months were identified in the Taabo HDSS database. 12 children 
died before baseline screening and 144 were absent for baseline screening
502 children (32 clusters) considered for the present 2x2 factorial analysis
Discontinued  intervention
- 1 received iron suppl.
Discontinued intervention
- 1 low Hb (<5 g/dl)
Discontinued intervention
- 1 received iron suppl.
Discontinued intervention
- 1 low Hb (<7 g/dl)
Discontinued intervention
- 1 received iron suppl.
- 1 low Hb (<5 g/dl)
Discontinued intervention
- 1 low Hb (<7 g/dl)
Discontinued intervention
- 1 low Hb (<7 g/dl)
Group 5: CF-FePP
127 children in 8 clusters
117 completed 6-month 
follow-up
87 children completed study 
and 127 were included in the 
analysis  
Lost to first follow-up
- 7 moved away
- 3 refused 
Lost to second follow-up
- 15 moved away
- 14 refused 
Discontinued intervention
- 1 received iron suppl.
After randomisation and 
before intervention
- 1 died
After randomisation and 
before intervention
- 1 died
Fig. 1 Trial profile. CF-FeFum complementary food fortified with NaFeEDTA + ferrous fumarate; CF-FePP complementary food fortified with 
NaFeEDTA + ferric pyrophosphate, IPT intermittent preventive treatment of malaria, Hb haemoglobin, HDSS health and demographic surveillance 
system
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received CF-FeFum. Children assigned to study group 5 
received CF-FePP.
In each of the 16 clusters where children (n =  250) 
received the CF-FeFum and in eight clusters where 
children (n = 127) received CF-FePP, one cooking area 
was installed. Trained women cooks prepared serv-
ings (25  mg dry matter) for each child individually, 
supervised the feeding, and recorded the daily amount 
of uneaten porridge for each child. Staff from Taabo 
HDSS monitored all cooking locations and cooks 
daily. The study investigator (or a study team member) 
monitored the progress of the study at least once every 
week.
Children allocated to study groups 1 and 3 received no 
nutritional intervention and the families were instructed 
to continue their normal dietary habits. From previous 
studies in Côte d’Ivoire, it has been found that young 
children (2–5 years) in rural areas consume mainly cas-
sava, plantain and sauces prepared with okra or pea-
nuts [15, 16], and have estimated a mean iron intake of 
5.5 mg/day and a mean phytic acid intake of 107 mg/day 
[15, 16]. This represents about 45–90 % of their recom-
mended daily intake, assuming a dietary iron absorption 
from 5 to 10 %.
IPT of malaria
At baseline, 3 and 6  months post-intervention, children 
assigned to IPT groups (groups 3 and 4) received one 
dose of SP (500  mg sulfadoxine plus 25  mg pyrimeth-
amine, or half of the dose if body weight ≤10  kg), and 
three daily doses of amodiaquine (200 mg on days 1 and 
2, and 100 mg on day 3, or half of the dose if body weight 
≤10 kg). Children assigned to groups 1, 2 and 5 received 
identical-appearing placebo tablets.
The trial medications (IPT and placebo) were pur-
chased from Kinapharma Limited (Accra, Ghana). They 
were coded using different colours for blister packs and 
packaging. To mask the bitter taste of amodiaquine, the 
trial medication was dissolved in approximately 4  ml 
Fanta (SOLIBRA; Abidjan, Côte d’Ivoire). The first dose 
was administered under supervision of a local nurse, 
the second and third doses were administered by chil-
dren’s mothers/guardians. The mothers/guardians were 
asked to keep empty pill packages for verification of drug 
administration. This was done by staff from Taabo HDSS, 
who visited all children 2 days after the first administra-
tion. Children who vomited or did not complete treat-
ment were re-dosed.
Blinding of treatments and follow‑up
Since half of the children did not receive the CF, this 
treatment was not blinded to either subjects or inves-
tigators. IPT was single blinded, i.e. the subject, staff 
from the HDSS, any caregivers (except study physician, 
see below) and the study nurses who administered the 
drugs were blinded, but the study supervisor (DG) and 
physician (LGA) had access to study group assignment. 
The concealment for IPT was assured by using two dif-
ferent colors for packaging (see above “IPT of malaria”). 
Sick children reporting to the local health centres were 
treated according to national guidelines irrespective of 
their study group assignment.
Mothers/guardians of participating children were 
encouraged to refer the child to the nearest health cen-
tre as soon as the child presented a symptom of illness, 
especially fever, and report the sick visit to Taabo HDSS 
staff. Each participating child received a study identity 
card to facilitate subject identification. At the time of 
study implementation, all consultations and treatments 
for children aged <5  years were free of charge in Côte 
d’Ivoire.
Outcomes and laboratory methods
Biomedical parameters were investigated at base-
line, after 6  months, and after 9  months. The follow-up 
blood samples were taken within a 2-week period, i.e. at 
6 months starting end of November until early December 
2012, and at 9 months starting at the beginning of March 
2013. The specified primary outcome was Hb concentra-
tion. Hb concentration, using a COULTER® Ac·T diff2™ 
(Beckman Coulter Inc.; Brea, USA), was measured. 
Anaemia was defined by Hb concentration below 11.0 g/
dl [17]. Secondary outcomes were iron status marker and 
Plasmodium prevalence.
Thick and thin blood films were stained with Giemsa 
and were examined microscopically for Plasmodium spe-
cies and parasitaemia, as described elsewhere [18]. Most 
of the infections were expected to be with P.  falciparum 
since infections with Plasmodium ovale and Plasmodium 
malariae are rare [2]. Clinical malaria was defined as a 
positive rapid diagnostic test (RDT; ICT ML01 malaria 
Pf kit; ICT Diagnostics, Cape Town, South Africa) and a 
tympanic temperature >37.5  °C or recent fever episodes 
reported by the mother/guardian.
The iron status marker plasma ferritin (PF), and the 
inflammation status markers α-1-acid-glycoprotein 
(AGP) and C-reactive protein (CRP), were meas-
ured with a sandwich enzyme-linked immunosorbent 
assay (ELISA), as described elsewhere [19]. ID was 
defined as PF <30  µg/l, according to recommenda-
tions by the World Health Organization (WHO) of ID 
in populations with high prevalence of infectious dis-
eases [20]. Concentrations below the detection limit 
were reported as detection limit. CRP above 5  mg/l 
or AGP concentrations above 1  g/l was considered as 
inflammation.
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Sample size and statistical analysis
The sample size calculation was based on a previous 
study among infants (aged 6–24  months) in this region 
of Côte d’Ivoire [12]. In that study, the standard deviation 
(SD) was 2.0  g/dl at a mean Hb concentration of 9.7  g/
dl. The aim was to detect an Hb difference of 0.8 g/dl, so 
allowing for a dropout rate of 20 %, it was estimated that 
125 children per group were needed to achieve a power 
level of 90 % at a 5 % level of significance.
After baseline assessment, it was decided to randomise 
the children into clusters for practical reasons and hence, 
we deviated from the protocol with randomisation on 
individual level. The effect of clusters was taken into 
account with multi-level modelling, whereas individu-
als are first and clusters the second level (as described 
below).
Data were analysed with STATA version 13.1 (Stata-
Corp LP; College Station, USA), including all randomised 
children. The residuals of the continuous variables were 
assessed for normality. Variables with non-normal dis-
tributed residuals were logarithmically transformed. 
An intention-to-treat analysis was pursued with mixed 
(fixed and random) linear regression multi-level mod-
els to account for random effects due to repeated meas-
ures within clusters (clusters are second level). A logistic 
regression was used taking into account random effect 
for analysis of prevalence (i.e. binary) data. For compari-
sons between groups, the models include study group 
assignment as fixed effects and children’s age as covari-
ate. CRP was added as covariate for analysis of PF as out-
come variable.
Treatment interaction (CF-FeFum  ×  IPT) was 
assessed by including study groups 1–4 in a 2 ×  2 fac-
torial analysis. Continuous outcomes are presented as 
adjusted differences and log-transformed outcomes 
as adjusted ratios. The mixed-effect multi-level mod-
els for the 2  ×  2 analysis include intervention as fixed 
effects and children’s age as covariate (clusters are sec-
ond level). CRP was added as covariate for analysis of PF 
as outcome variable. All models for the 2 ×  2 factorial 
analysis were assessed for treatment interactions (CF-
FeFum ×  IPT ×  time) for primary and secondary out-
comes. If no interaction was found, the 2 ×  2 factorial 
analyses were presented. In case of interaction, only the 
group comparison was presented.
Results
Six hundred eighty-four children were assessed for eligi-
bility, of which 629 children were assigned to 40 clusters; 
these clusters were randomly assigned to five groups. 
Baseline characteristics are summarised in Table 1.
Compliance rates of porridge consumption were 92.5, 
95.0 and 94.8  % for the study porridge administered to 
groups 2, 4 and 5, respectively. Compliance with IPT 
and IPT-placebo for study groups 1–5 were 97.6, 96.0, 
96.9, 97.6 and 96.8  % at the first treatment (baseline), 
95.2, 94.4, 92.9, 92.0 and 93.7  % at 3  months, and 91.1, 
88.1, 81.1, 84.0 and 90.6 % at 6 months. Reasons for non-
compliance of IPT of malaria included: children refusing 
to swallow the drug, vomiting after repeated dosing, or 
mothers/guardians did not consider the IPT important 
for their children.
Table 1 Baseline characteristics of the randomised study groups
Data are mean (SD), n (%) or median (interquartile range). Anaemia: Hb concentration <11 g/dl; iron deficiency: plasma ferritin <30 µg/l
CF-FeFum complementary food fortified with NaFeEDTA + ferrous fumarate, CF-FePP complementary food fortified with NaFeEDTA + ferric pyrophosphate, IPT 
intermittent preventive treatment of malaria
a parasites/µl of blood, only presented for infected children
Intervention(s) Group 1 (n = 125) Group 2 (n = 126) Group 3 (n = 127) Group 4 (n = 124) Group 5 (n = 127)
Control CF‑FeFum IPT CF‑FeFum + IPT CF‑FePP
Clusters 8 8 8 8 8
Girls 65 (52.0 %) 57 (45.2 %) 65 (51.2 %) 65 (52.4 %) 64 (50.2 %)
Age (mo) 23.3 (6.9) 23.5 (7.2) 22.9 (7.0) 23.8 (6.4) 23.4 (7.1)
Haemoglobin conc. (g/dl) 9.8 (1.3) 9.9 (1.2) 9.8 (1.1) 9.9 (1.1) 9.6 (1.2)
Anaemia 102 (81.6 %) 101 (80.2 %) 108 (85.0 %) 105 (84.7 %) 110 (86.6 %)
Plasma ferritin (µg/l) 37.7 (18.3–72.4) 36.2 (21.6–66.0) 37.5 (16.9–74.9) 36.7 (18.2–68.4) 53.0 (28.3–115.7)
Iron deficiency 47 (37.4 %) 50 (40.0 %) 53 (42.1 %) 54 (43.9 %) 34 (26.8 %)
Plasmodium prevalence 78 (62.1 %) 73 (57.7 %) 78 (61.4 %) 66 (53.3 %) 84 (66.1 %)
P. falciparum parasitaemiaa 1200 (208–5200) 600 (128–3400) 2240 (880–6920) 688 (240–4000) 2140 (400–7500)
Height (cm) 79.2 (6.8) 78.5 (7.5) 79.7 (6.7) 79.7 (6.6) 78.6 (6.8)
Body weight (kg) 10.5 (9.0–12.0) 11.0 (9.0–12.0) 11.0 (9.5–13.0) 10.8 (9.5–12.4) 10.0 (9.0–12.0)
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As shown in Fig.  1, about one-third of the children 
were lost to follow-up over the 9  months intervention. 
Protocol deviation concerned nine children (1.4 %) who 
discontinued the interventions: three children were 
excluded because of Hb <7  g/dl over the course of the 
study and were treated with iron supplementation; two 
were excluded because of Hb <5  g/dl and were treated 
with blood transfusions; and four were excluded because 
they received iron supplements by the parents/guard-
ians. Eight children died and the cause of death was 
determined by verbal autopsy. Two deaths occurred 
before the intervention started but after baseline 
screening and randomisation. The remaining six deaths 
occurred over the course of the 9-month study period: 
none died in groups 1 and 5; in group 2, two died of 
pneumonia and one from malaria; in group 3, one died 
from malaria with subsequent anaemia; and in group 4, 
two died from malaria.
Haemoglobin and anaemia
Haemoglobin concentration did not differ between the 
five groups at baseline. The observed increase in the five 
groups was not different after 9 months (Table 2). After 
6 months, a transient effect (during the rainy season) was 
observed, when Hb concentration increased significantly 
in children in group 4 (receiving IPT and CF-FeFum) 
when compared to group 1 (control, P = 0.014) or group 
2 (children receiving CF-FeFum, P  =  0.025) (Fig.  2). 
After 9  months, the decrease of anaemia was signifi-
cantly higher in groups 3, 4 and 5 than in groups 1 or 2 
(Table 2).
Treatment interactions (CF-FeFum  ×  IPT) were 
assessed with the 2  ×  2 factorial analysis including 
groups 1–4. No interaction was found between interven-
tions for Hb concentration (P = 0.89). After 9 months, no 
effect of interventions on Hb concentration was found. 
Similar to the five group comparison, we observed a 
transient effect after 6  months, when Hb concentra-
tion increased significantly in children receiving IPT 
(n  =  251; adjusted mean difference 0.35  g/dl [95  % CI 
0.04–0.66; P  =  0.027]). The increase of Hb concentra-
tion after 9  months was no longer significant (0.24  g/dl 
[95  % CI −0.10 to 0.59; P  =  0.16]) (Table  3). Children 
receiving IPT showed lower odds of being anemic after 6 
and 9 months (odds ratio [OR], 0.46 [95 % CI 0.24–0.90; 
P = 0.023] and OR, 0.46 [95 % CI 0.23–0.90; P = 0.024]) 
(Table 4). The iron fortified CF-FeFum had no effect on 
anaemia prevalence after 6 and 9 months (OR, 0.64 [95 % 
CI 0.33–1.25; P = 0.19] and OR, 0.85 [95 % CI 0.43–1.68; 
P = 0.64]). 
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Fig. 2 Haemoglobin concentration at baseline, 6 and 9 months for each study group. CF-FeFum complementary food fortified with 
NaFeEDTA + ferrous fumarate, CF-FePP complementary food fortified with NaFeEDTA + ferric pyrophosphate, IPT intermittent preventive treatment 
of malaria, Hb haemoglobin
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Table 2 Group comparison analysis
Data are mean ± SD, % or median (IQR). Changes between baseline to 6 months and baseline to 9 months were compared between groups with random effect 
models. Anaemia: Hb concentration <11 g/dl; iron deficiency: plasma ferritin <30 µg/l; inflammation: CRP ≥5.0 mg/l or AGP ≥1.0 g/l; and P. falciparum parasitaemia: 
parasites/µl blood, only presented for infected children at the specific time points
CF-FeFum complementary food fortified with NaFeEDTA + ferrous fumarate, CF-FePP complementary food fortified with NaFeEDTA + ferric pyrophosphate, IPT 
intermittent preventive treatment of malaria, AGP α-1-acid-glycoprotein, CRP C-reactive protein, Hb haemoglobin concentration, IQR interquartile range
*/**/*** Increase/decrease in groups 2, 3, 4 and 5 significantly different compared to increase/decrease in group 1, *P < 0.05, ** P < 0.01, *** P < 0.001
Ψ /ΨΨ/ΨΨΨ Increase/decrease in groups 3, 4 and 5 significantly different compared to group 2, ΨP < 0.05, ΨΨP < 0.01, ΨΨΨ P < 0.001
† /††/††† Increase/decrease in groups 4 and 5 significantly different compared to group 3, †P < 0.05, ††P < 0.01, ††† P < 0.001
¥ /¥¥/¥¥¥ Increase/decrease in group 5 significantly different compared to group 4, ¥P < 0.05, ¥¥P < 0.01, ¥¥¥P < 0.001
Group 1 Group 2 Group 3 Group 4 Group 5
Control CF‑FeFum IPT CF‑FeFum + IPT CF‑FePP
Participants (n)
 Baseline 125 126 127 124 127
 6 months 104 111 103 114 117
 9 months 76 81 77 82 87
Hb concentration (g/dl)
 Baseline 9.8 ± 1.3 9.9 ± 1.2 9.8 ± 1.1 9.9 ± 1.1 9.6 ± 1.2
 6 months 9.9 ± 1.3 9.9 ± 1.3 10.0 ± 1.3 10.4 ± 1.4*, Ψ 10.0 ± 1.1
 9 months 10.3 ± 1.3 10.4 ± 1.2 10.5 ± 1.2 10.5 ± 1.2 10.5 ± 1.2
Anaemia
 Baseline 81.6 % 80.2 % 85.0 % 84.7 % 86.6 %
 6 months 79.8 % 77.5 % 77.7 % 62.3 %*, Ψ, † 81.9 %¥
 9 months 71.1 % 70.4 % 63.6 %*, Ψ 56.1 %**, ΨΨ 65.5 %*, Ψ
Plasma ferritin (µg/l)
 Baseline 37.7 (18.3–72.4) 36.2 (21.6–66.0) 37.5 (16.9–74.9) 36.7 (18.2–68.4) 53.0 (28.4–115.7)†, ¥
 6 months 60.7 (35.1–114.0) 102.4 (48.3–159.5)** 56.5 (26.9–92.9)ΨΨ 70.9 (42.5–133.0)*, † 69.1 (41.8–139.7)Ψ, ¥
 9 months 49.6 (26.2–96.0) 66.5 (45.4–117.4) 39.4 (23.6–69.3)ΨΨ 62.8 (39.2–92.4)† 62.6 (41.1–107.2)¥
Iron deficiency
 Baseline 37.4 % 40.0 % 42.1 % 43.9 % 26.7 %†, ¥
 6 months 19.2 % 5.4 %** 27.5 %ΨΨ 12.3 %†† 8.6 %††
 9 months 29.3 % 3.7 %*** 36.4 % ΨΨ 15.8 %Ψ,†† 10.3 %**, ††
Anaemia and iron deficiency
 Baseline 33.3 % 32.8 % 31.7 % 38.2 % 23.6 %¥
 6 months 15.4 % 3.6 %** 19.6 % ΨΨ 4.4 %**,††† 4.3 %*,††
 9 months 18.7 % 1.2 %** 26.0 % ΨΨ 3.7 %**,†† 3.4 %**, ††
CRP (mg/l)
 Baseline 2.8 (1.0–11.1) 3.4 (1.4–8.7) 4.2 (1.4–12.0) 3.0 (1.1–7.3) 5.9 (1.9–21.3)*,Ψ,¥
 6 months 5.1 (1.8–18.6) 4.6 (1.2–20.4) 3.6 (1.2–17.3) 3.8 (0.8–17.0) 4.8 (1.5–14.6)*,Ψ
 9 months 2.6 (1.0–7.3) 4.3 (1.0–13.2) 1.8 (0.5–5.9) 1.8 (0.9–5.5) 3.2 (1.3–14.8)
AGP (g/l)
 Baseline 1.12 (0.90–1.40) 1.27 (1.01–1.54) 1.22 (0.96–1.62) 1.16 (0.92–1.51) 1.26 (0.96–1.65)
 6 months 1.13 (0.88–1.41) 1.25 (0.92–1.54) 1.23 (0.80–1.55) 1.04 (0.81–1.44)† 1.10 (0.85–1.40)
 9 months 1.07 (0.78–1.44) 1.13 (0.85–1.36) 1.10 (0.88–1.35) 1.02 (0.79–1.23)*,†† 1.06 (0.79–1.28)
Inflammation
 Baseline 65.8 % 76.8 % 76.2 % 73.2 % 76.4 %
 6 months 72.1 % 74.8 % 69.6 % 57.0 %Ψ,†† 65.5 %
 9 months 57.3 % 64.2 % 63.6 % 56.1 %†† 57.5 %
Plasmodium prevalence
 Baseline 62.1 % 57.7 % 61.4 % 53.3 % 66.1 %
 6 months 62.5 % 55.0 % 44.7 %* 45.6 %* 64.7 %¥,†
 9 months 44.7 % 46.9 % 35.1 %Ψ 34.1 %Ψ 47.1 %
P. falciparum parasitaemia (parasites/µl blood)
 Baseline 1200 (208–5200) 600 (128–3400) 2240 (880–6920) 688 (240–4000) 2140 (400–7500)*,¥
 6 months 4160 (1200–10,480) 1880 (720–6360) 4400 (256–17,080) 1820 (480–11,200) 2720 (640–9040)
 9 months 2740 (1080–14,640) 2740 (840–8040) 4520 (440–20,320) 1920 (240–4080)Ψ, † 4800 (960–9560)Ψ
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Iron status
At baseline, the PF concentration was slightly higher in 
children in group 5 (receiving CF-FePP) than in chil-
dren in groups 3 and 4 (Table  2). At 6  months, the PF 
concentration increased significantly more in groups 
2 and 4 than in groups 1, 3 and 5. After 9  months, the 
increases in groups 2 and 4 were higher than in group 3. 
The increase after 9 months in group 4 was higher than in 
group 5 (Table 2). ID decreased significantly in all three 
groups receiving iron for 9  months (groups 2, 4 and 5). 
The decrease of ID in group 2 was higher than in group 
4 (Table 2).
In the 2 × 2 factorial analysis, no treatment interaction 
on PF concentration (P = 0.55) was found. From baseline 
to 6 and 9  months, the PF concentration was increased 
by 33 % (95 % CI 14–51 %) and 36 % (95 % CI 16–56 %), 
respectively, in children receiving CF-FeFum (Table  3). 
Children receiving CF-FeFum were significantly less 
likely to be iron deficient after 6 months (OR, 0.28 [95 % 
CI 0.14–0.56; P < 0.001]) and 9 months (OR, 0.19 [95 % 
CI 0.09–0.40; P  <  0.001]) (Table  4). The 2 ×  2 factorial 
analysis showed no effect by IPT on ferritin concentra-
tion and ID prevalence.
Plasmodium prevalence and inflammation
Plasmodium prevalence was not different between the 
five study groups at baseline. After 6 months (end of rainy 
season), the decrease of malaria prevalence in groups 3 
and 4 (all receiving IPT) was significantly higher than in 
groups 1, 2 and 5 (all receiving IPT-placebo) (Table  2). 
After 9  months, the Plasmodium prevalence decreased 
in all groups, but the decrease in study 2 was lower than 
in groups 3 and 4. Inflammation parameters (AGP and 
CRP) in all five groups showed no major differences at 
baseline, except CRP in group 5 was significantly higher 
than in groups 1, 2 and 4.
In the 2 × 2 factorial analysis, no interaction between 
the two treatments on malaria prevalence was found 
(P = 0.78), on AGP concentration (P = 0.18) or on CRP 
(P = 0.52). In the 2 × 2 factorial analysis, neither inter-
vention significantly affected the P.  falciparum preva-
lence at 6 or 9 months follow-up. CRP concentration was 
reduced by 47 % after 9 months (95 % CI 2–92 %) in chil-
dren receiving IPT (Table 3). Children receiving IPT had 
lower odds to have an elevated inflammation status after 
6 months (OR, 0.52 [95 % CI 0.29–0.94; P = 0.030]), but 
this effect was not observed after 9 months (Table 4).
Figure  3 shows the prevalence of anaemia in the five 
study groups. Anaemia was stratified into anaemia with 
ID (spotted) or anaemia without ID (shaded). This figure 
displays the dynamic of anaemia with and without ID in 
the present study population over the 9 months period.
Discussion
This randomised controlled trial examined the effects 
of CF fortified with highly bioavailable iron compounds 
and IPT of malaria in 12- to 36-month-old children in 
an area of intense malaria transmission in West Africa. 
To the authors’ knowledge, this is the first trial assessing 
the treatment interaction of iron-fortified CF and IPT of 
Table 3 Main effects of iron fortified CF-FeFum and IPT of malaria
a Assignment at baseline
b Adjusted for age, Hb concentration at baseline and factorial design
c Adjusted for age, C-reactive protein concentration, PF concentration at baseline and factorial design
d Adjusted for age, C-reactive protein concentration at baseline and factorial design
The effects were assessed in 12- to 36-month-old Ivorian children at 6 and 9 months. The estimations are based on a 2 × 2 factorial analysis using a linear regression 
model taking into account random effects
Effect of iron fortified complementary food Effect of intermittent preventive treatment 
of malaria
Received CF‑FeFuma n = 250 Received IPTa n = 251
No CF‑FeFuma n = 252 IPT‑placeboa n = 251
Adjustedb difference of Hb concentration g/dl (95 % CI)
 6 months 0.11 (−0.20 to 0.42; P = 0.49) 0.35 (0.04 to 0.66; P = 0.027)
 9 months −0.08 (−0.42 to 0.26; P = 0.65) 0.24 (−0.10 to 0.59; P = 0.16)
Adjustedc ratios of log-transformed PF concentration (95 % CI)
 6 months 1.33 (1.14 to 1.51; P = 0.001) 0.95 (0.76 to 1.13; P = 0.58)
 9 months 1.36 (1.16 to 1.56; P < 0.001) 0.91 (0.70 to 1.11; P = 0.37)
Adjustedd ratios of log-transformed CRP concentration
 6 months 1.04 (0.63 to 1.45; P = 0.84) 0.77 (0.36 to 1.18; P = 0.27)
 9 months 1.10 (0.65 to 1.55; P = 0.67) 0.53 (0.08 to 0.98; P = 0.039)
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Table 4 Odds ratios for anaemia, iron deficiency, malaria and inflammation prevalence
a Assignment at baseline
b Adjusted for age
c Adjusted for age and CRP concentration
d Inflammation is defined as CRP >5 mg/l and/or AGP >1 g/l
Odds ratios were assessed in 12- to 36-month-old Ivorian children at 6 and 9 months. The estimations are based on a 2 × 2 factorial analysis using a logistic regression 
model taking into account random effects
Effect of iron fortified complementary food Effect of intermittent preventive treatment 
of malaria
Received CF‑FeFuma n = 250 Received IPTa n = 251
No CF‑FeFuma n = 252 IPT‑placeboa n = 251
Odds ratiosb of anaemia (Hb concentration <11 g/dl) (95 % CI)
 6 months 0.64 (0.33 to 1.25; P = 0.19) 0.46 (0.24 to 0.90; P = 0.023)
 9 months 0.85 (0.43 to 1.68; P = 0.64) 0.46 (0.23 to 0.90; P = 0.024)
Odds ratiosc of iron deficiency (plasma ferritin concentration <30 µg/l) (95 % CI)
 6 months 0.28 (0.14 to 0.56; P < 0.001) 1.52 (0.76 to 3.04; P = 0.23)
 9 months 0.19 (0.09 to 0.40; P < 0.001) 1.64 (0.79 to 3.42; P = 0.19)
Odds ratiosb of malaria prevalence (P. falciparum) (95 % CI)
 6 months 1.17 (0.68 to  2.01; P = 0.58) 0.59 (0.34 to 1.02; P = 0.057)
 9 months 1.30 (0.71 to 2.39; P = 0.39) 0.61 (0.33 to 1.12; P = 0.11)
Odds ratiosb of the inflammation statusd (95 % CI)
 6 months 0.66 (0.37 to 1.19; P = 0.17) 0.52 (0.29 to 0.94; P = 0.030)
 9 months 0.82 (0.44 to 1.51; P = 0.52) 0.77 (0.42 to 1.43; P = 0.41)
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Fig. 3 Prevalence of anaemia at baseline, 6 and 9 months for each study group. Anaemic children are separated into children with iron deficiency 
and no iron deficiency. Iron deficiency was reduced in anaemic children receiving CF-FeFum or CF-FePP. IPT modestly reduced anaemia, without 
affecting iron deficiency. CF-FeFum complementary food fortified with NaFeEDTA + ferrous fumarate, CF-FePP complementary food fortified with 
NaFeEDTA + ferric pyrophosphate, IPT intermittent preventive treatment of malaria
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malaria with a 2 × 2 factorial design. The main findings 
are: (1) no interaction between IPT of malaria and CF on 
Hb concentration, anaemia or ID; (2) iron fortified CF 
had no effect on Hb concentration or anaemia prevalence 
but substantially decreased the prevalence of ID; (3) IPT 
of malaria modestly reduced anaemia; and (4) iron forti-
fication with FeFum or FePP had the same effect on Hb 
concentration, although anaemia decreased more in chil-
dren receiving FePP.
Despite covering >90  % of the iron RNI with com-
pounds expected to have high bioavailability, after 
9  months, iron fortification had no significant effect on 
Hb concentration or anaemia prevalence. The results dif-
fer from a subgroup analysis from a recently published 
Cochrane review that reported a positive effect of iron 
fortification at point of consumption with micronutri-
ent powders on anaemia prevalence in malaria-endemic 
regions [6]. However, micronutrient powders contain 
more iron than fortified complementary foods and, in 
the four selected studies utilised for the subgroup analy-
sis, the malaria prevalence was below 10 % in one study, 
malaria parasitaemia was poorly defined in the other 
three studies and concomitant anti-malarial treatments 
were not reported. Hence, the effect of iron fortification 
on anaemia in malaria-endemic regions remains unclear.
ID was defined as PF <30 µg/l and was based on recom-
mendations from WHO [17] for populations with high 
prevalence of infections. The prevalence of inflammation 
in the study population was high; more than two-thirds 
of the children had an elevated CRP and/or AGP. The 
potential confounding effect of inflammation was taken 
into account by adjusting the linear regression models for 
CRP concentration. Both iron fortified CF increased PF 
and sharply decreased ID, consistent with two previous 
studies conducted in Côte d’Ivoire that failed to show a 
significant effect of iron fortification on Hb concentra-
tion in school-aged children but did decrease ID [21, 22].
Treatment with SP/AQ clears P.  falciparum parasi-
taemia [23], and is protective against reinfection for 
28–35  days [24, 25]. Malaria transmission is perennial 
in this part of Côte d’Ivoire, with high entomological 
inoculation rates (117–409 infectious bites per person 
per year) [26]. Hence after the protective effect of the 
IPT had faded, children were at high risk of re-infection 
and many of them indeed became re-infected between 
the IPT treatments. However, the protection of each IPT 
course was sufficiently long to reduce the risk of anaemia. 
This protective effect of IPT against anaemia is consist-
ent with a meta-analysis of six IPT trials conducted in 
areas where malaria transmission is seasonal or perennial 
with the reported relative risk of anaemia decreased by 
21 % (95 % CI 8–33 %) [5]. In the present study, although 
children assigned to IPT were less likely to be anemic, the 
increase of the adjusted Hb concentration was not sig-
nificantly different when compared to children receiving 
placebo. In other words, at study end, the differences of 
Hb concentrations were small despite the apparent fall in 
frequency of anaemia in children receiving IPT (Fig. 2).
No evidence was found that IPT of malaria improves the 
efficacy of iron fortified CF by facilitating iron absorption 
or erythropoiesis, which are reported to be diminished 
during P. falciparum infection [7, 27]. However, both iron 
fortified CFs (CF-FeFum and CF-FePP) improved iron sta-
tus in children similarly regardless of whether or not they 
received IPT. This finding may be explained by a recent 
study reporting that serum hepcidin in iron deficient chil-
dren is decreased, even in the presence of P.  falciparum 
infection [28]. The lack of an interaction between both 
interventions on anaemia prevalence is consistent with a 
previous study in 12- to 16-week-old Tanzanian infants 
who received iron supplementation with or without IPT 
of malaria [29]. This study found no additional effect on 
anaemia when iron supplementation was combined with 
IPT. Compared to the present study, the Tanzanian chil-
dren were much younger and iron was given as higher 
dose supplements over a shorter period. However, the 
fact that IPT of malaria in the Tanzanian and the current 
study had a stronger effect on anaemia prevalence than 
iron alone suggests that infection with P. falciparum is the 
predominant risk factor for anaemia in young children.
The present study was implemented at the transition 
zone of tropical rainforest in the South and the savannah in 
the North [30] and, although the transmission of malaria is 
perennial in this part of Côte d’Ivoire, there is also some 
natural fluctuation in malaria transmission between the 
dry and the rainy season [3, 31]. The study included the 
rainy season (baseline to 6  months) and the dry season 
(6–9  months). The prevalence of P.  falciparum infec-
tion in the control group did not change during the first 
6  months, but it decreased by almost one-third over the 
last 3 months. Although Hb concentration did not change 
in the control group during the first 6 months, it increased 
during the last 3 months of intervention. The effect of IPT 
on Hb appeared to be stronger at the end of the rainy sea-
son (at 6 months). This suggests the abatement of malaria 
transmission during the dry season likely influenced the 
impact of the treatments, and may have been responsible 
for the differences in outcomes at 6 and 9 months.
The present study has several strengths. It was con-
ducted in infants and young children in a rural setting 
of West Africa where anaemia is common and malaria 
transmission is intense. Beside the comparison of the five 
groups, a 2 × 2 factorial design was employed to assess 
potential interactions between CF and IPT and compli-
ance was high for both interventions. Iron compounds 
with high bioavailability were used that had previously 
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demonstrated efficacy [9]. An effective anti-malarial regi-
men with a relatively long half-life was used, but, never-
theless, many children became re-infected by the time of 
the next follow-up.
Limitations of the present study include possible con-
founding by seasonal variations in malaria transmission, 
the relatively high drop-out rate (attrition bias), and the 
use of a single iron biomarker (i.e. PF) to define iron sta-
tus. Inherited haemoglobinopathies are unlikely to play 
a major role in anaemia in this population, as previous 
studies in this region reported 83  % of subjects to have 
normal Hb genotype, and only 8, 7 and 1 % carried an S 
allele, C allele, and had sickle cell anaemia, respectively 
[12]. Likewise, other micronutrient deficiencies, such as 
vitamin A, although present, were not associated with 
anaemia in the same region [12]. Hookworm contributes 
to anaemia in many tropical regions, but the prevalence 
of hookworm was very low in our study subjects, similar 
to an earlier investigation [12].
Conclusions
The results of the present study confirm that anaemia is 
a major public health problem in young children in Côte 
d’Ivoire and requires urgent action. About half of the 
anaemic children were iron deficient and the iron forti-
fied CF almost eliminated ID, but against the authors’ 
expectation, it did not decrease anaemia prevalence. This 
observation is in line with a recently published Cochrane 
review including anemic children living in malaria-
endemic regions receiving iron supplementation and IPT 
for a 12-week period [32]. The authors reported a modest 
effect of IPT on Hb concentration, irrespective of whether 
the children received supplemental iron (sub-group 
analysis). The Cochrane review and the current findings 
argue that the effect of IPT on anaemia should be further 
investigated, maybe in combination with the reduction of 
malaria transmission, to be achieved through a combina-
tion of vector control strategies (e.g. removal of potential 
breeding sites, use of long-lasting insecticidal nets, indoor 
residual spraying and IPT of malaria). The findings of the 
present study further show that iron fortification of CF 
is an effective fortification strategy to prevent negative 
health consequences due to ID. Moreover, these findings 
underline the multiple aetiologies of anaemia in tropical 
settings and point to combined interventions being neces-
sary for its prevention or treatment.
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